XKRX
036220
Market cap67mUSD
Oct 08, Last price
6,560.00KRW
1D
-3.39%
1Q
11.19%
IPO
-83.61%
Name
Osang HealthCare Co Ltd
Chart & performance
P/E
—
P/S
—
EPS
225.92
Div yield, %
—
Shrs. gr., 5y
1.92%
Rev. gr., 5y
-12.99%
Revenues
128.63b
+59.81%
Net income
3.11b
P
CFO
6.21b
P
Dividend
Mar 30, 2026200 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Osang Healthcare Co.,Ltd, based in Anyang, South Korea, is a company focused on the innovation, advancement, and global commercialization of diverse diagnostic biosensing solutions. Their comprehensive product offerings include tests for key health markers such as blood glucose, hemoglobin A1c, and cholesterol, in addition to sophisticated immuno- and molecular diagnostic technologies. These cutting-edge products reach approximately 110 nations across the globe. Established in 1996, the firm operated as Infopia Co., Ltd. until its rebranding to Osang Healthcare Co.,Ltd in April 2017.
Key people
President, Co-Chief Executive Officer, Director · since 2025
Byeong Yeol Yoo
Co-Chief Executive Officer, Director · since 2025
Mi Suk Park
Managing Director
Byeong Chang Son
Managing Director
Cheol Hui Jung
Assistant Managing Director · since 2024
Chairman · since 2022
Sang Hwan Ahn
Non-Executive Independent Director
Jong Nam Ahn
Non-Executive Independent Director
Sang Wuk Han
Non-Executive Independent Director
Jong Min Lee
Non-Executive Independent Director · since 2024
Yeo Min Yoon
Non-Executive Independent Director
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT |